文献速递肺结节与肺癌

克唑替尼对比观察或安慰剂用于已手术切除的早期ALK阳性非小细胞肺癌(ECOG-ACRIN E4512):3期试验

Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2026-08-25

E4512是一项随机对照3期试验,评估辅助克唑替尼对已切除早期ALK阳性NSCLC无病生存期(DFS)的影响。辅助克唑替尼未延长DFS,不建议作为已切除ALK阳性NSCLC的辅助治疗。

要点

  • 辅助克唑替尼未改善已切除早期ALK阳性NSCLC的无病生存期。
  • 克唑替尼组58%发生≥3级不良事件,27%发生严重不良事件。
  • 因FDA批准辅助阿来替尼,该试验提前停止入组。

核心结论

  • 辅助克唑替尼不能延长已手术切除ALK阳性NSCLC患者的无病生存期,不建议作为辅助治疗。

研究设计与样本

  • 随机对照3期试验,在美国、关岛和波多黎各1618个站点开展,计划入组168例,实际入组166例,按1:1随机分配至克唑替尼250mg口服每日两次(85例)或观察(81例),最长2年。
  • 入组条件为已切除NSCLC肿瘤直径≥4cm或淋巴结阳性、切缘阴性、未接受新辅助治疗、当地或中心检测ALK阳性、ECOG体能状态0-1;允许但不要求辅助化疗。
  • 主要终点为中心检测ALK阳性意向治疗人群的DFS,以风险比及90%和95%CI呈现。

主要发现

  • 中心确认ALK阳性153例(92%),其中女性99例(65%)、男性54例(35%)、白人121例(79%)。
  • 克唑替尼组46例(58%)发生任何归因的≥3级不良事件,最常见腹泻8例(10%)、水肿4例(5%)、高血压4例(5%),包括1例非治疗相关死亡;21例(27%)发生严重不良事件,最常见呼吸困难3例(4%)。

关键数值与推荐

  • ≥3级不良事件发生率58%,严重不良事件发生率27%。

临床怎么用

  • 已手术切除的早期ALK阳性NSCLC患者不应推荐辅助克唑替尼治疗。
  • 临床决策需结合FDA已批准辅助阿来替尼的背景,该试验因阿来替尼获批提前停止入组。

局限性

  • 实际入组166例,未达到计划168例,且因FDA批准辅助阿来替尼提前停止入组。
  • 观察组由初始双盲安慰剂改为观察,可能影响盲法实施。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Crizotinib is an established first-generation anaplastic lymphoma kinase (ALK) inhibitor approved for the treatment of advanced ALK-positive non-small-cell lung cancer (NSCLC). E4512 aimed to evaluate the effect of adjuvant crizotinib on disease-free survival (DFS) in patients with resected, early-stage ALK-positive NSCLC. METHODS: In this randomised, controlled, phase 3 trial conducted in 1618 sites across the USA, Guam, and Puerto Rico, patients were randomly assigned 1:1 by computer-generated sequence to receive crizotinib 250 mg orally twice daily or observation (changed from initial double-blind placebo) for up 2 years. Eligible patients had resected NSCLC tumours that were 4 cm or larger in diameter or lymph node-positive, negative surgical margins, no neoadjuvant therapy, ALK positivity by local or central testing, and an Eastern Cooperative Oncology Group performance status of 0-1. Adjuvant chemotherapy was allowed but not required. Stratification factors were stage, previous radiation therapy, and sex. The primary endpoint was disease-free survival (DFS) in the centrally tested ALK-positive intention-to-treat population and presented as hazard ratio with 90% and 95% CI. The trial was registered at ClinicalTrials.gov (NCT02201992) and is completed. Safety was assessed in all patients whose tumours tested ALK-positive and who received the study drug. FINDINGS: Between Aug 18, 2014, and May 10, 2024, 166 patients (of 168 planned) were enrolled (85 to crizotinib and 81 to observation). Accrual was stopped when the US Food and Drug Administration approved adjuvant alectinib for resected ALK-positive NSCLC. Overall, 153 (92%) patients had centrally confirmed ALK-positive tumours. Among these 153 individuals, 99 (65%) were female, 54 (35%) were male, and 121 (79%) were White. After a median follow-up of 65·7 months (IQR 37·5-85·6), median DFS was 74·6 (95% CI 71·2 to not assessable) months in the crizotinib group and 75·1 (64·7 to NA) months in the observation group (HR 1·08 [90% CI 0·67-1·73; 95% CI 0·61-1·90; p=0·80). In the crizotinib group, 46 (58%) patients had grade 3 or higher adverse events of any attribution (most commonly diarrhoea, in eight [10%] patients; oedema, in four [5%] patients; and hypertension, in four [5%] patients), including one death that was not deemed treatment-related. 21 (27%) patients had serious adverse events, most commonly dyspnoea (three [4%] patients), abdominal pain (two [3%] patients), thromboembolic event (two [3%] patients), diarrhoea (two [3%] patients), dehydration (two [3%] patients), and hypertension (two [3%] patients). INTERPRETATION: Adjuvant crizotinib does not prolong DFS in patients with surgically resected ALK-positive NSCLC. These findings suggest that crizotinib should not be recommended as an adjuvant therapy for patients with resected ALK-positive NSCLC. FUNDING: National Cancer Institute of the US National Institutes of Health.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Gerber DE, Wang Y, Langer CJ, et al. Crizotinib versus observation or placebo for surgically resected early-stage ALK-positive non-small-cell lung cancer (Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E4512): a phase 3 trial. Lancet Respir Med. 2026. PMID: 42641639. doi:10.1016/S2213-2600(26)00192-X

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。